2022 American Transplant Congress
Cytomegalovirus Prevention in Kidney and Pancreas Transplant Recipients: A Successful Pharmacist-Led Multidisciplinary Approach
University of Virginia Health, Charlottesville, VA
*Purpose: In response to high cytomegalovirus (CMV) infection and increasing ganciclovir (GCV)-resistance rate, a pharmacist-led multidisciplinary task force was created to manage CMV prophylaxis (ppx).…2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir or Valganciclovir for EBV Prophylaxis: A Randomized Controlled Trial
*Purpose: EBV viremia post-kidney transplant (KTx) has no proven prophylaxis.*Methods: In this randomized, open-label trial [NCT01329185], adult and pediatric recipients were randomly assigned (1:1) to…2022 American Transplant Congress
Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants
Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC
*Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…2021 American Transplant Congress
Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility
*Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
1Albany Medical Center, Albany, NY, 2Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…2019 American Transplant Congress
Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis
*Purpose: Cytomegalovirus (CMV) disease continues to stand as a significant threat to the longevity of renal transplants in children. More pediatric recipients are CMV negative…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…
American Transplant Congress abstracts